Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
RESEARCH TOOLSreports
Bioxcel Therapeutics (BTAI) Stock Price & Analysis
1,237 Followers
BTAI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.91 - $29.56
Previous Close$2.56
Volume147.56K
Average Volume (3M)1.53M
Market Cap
$94.81M
Enterprise Value$130.63M
Total Cash (Recent Filing)$65.22M
Total Debt (Recent Filing)$101.04M
Price to Earnings (P/E)-0.4
Beta1.33
Next Earnings
May 09, 2024EPS Estimate
-$0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.16
Shares Outstanding30,576,671
10 Day Avg. Volume412,640
30 Day Avg. Volume1,532,357
Standard Deviation0.35
R-Squared0.00426
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.37
Price to Sales (P/S)208.18
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue94.66
Enterprise Value/Gross Profit1.09K
Enterprise Value/Ebitda-0.80
Forecast
1Y Price Target
$6.30Price Target Upside145.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bioxcel Therapeutics News
PremiumCompany Announcements
Bioxcel Therapeutics Advances SERENITY Trial and Strategy
PremiumCompany Announcements
Bioxcel Therapeutics Advances Alzheimer’s Agitation Treatment Trial
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBTAI's TRANQUILITY and SERENITY programs aim to expand the utility and revenue potential for their lead asset Igalmi/BXCL501.
Financial HealthThe recent financing is expected to extend BTAI's cash runway into 4Q24, offering financial stability for the company's operations.
Label ExpansionThe SERENITY III program aims to make BXCL501 available to millions of additional patients by potentially expanding its label for outpatient use at home.
Bears Say
Drug Development And Approval DelaysA delayed launch timeline for '501 in AD agitation has been adjusted from 2027 to now 2028, indicating potential setbacks in development.
Financial PerformanceRevenue of $376K came in below expectations, and the company's cash reserves decreased significantly.
Financing And Strategy ConcernsThe exact next steps, more granular timelines and approximate costs for the '501 programs remain unclear, maintaining a financing overhang on the company.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $1.91 and its highest was $29.56 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Currently, no data Available
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is May 09, 2024 which is in 4 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Bioxcel Therapeutics Inc released its earnings results on Mar 12, 2024. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.917 by $0.157.
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate is -$0.68.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 37,034,515 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Bioxcel Therapeutics Inc reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.917. Following the earnings report the stock price went down -4.483%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Among the largest hedge funds holding Bioxcel Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics Inc’s shares valued at N/A.
---
Bioxcel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.30 (145.14% Upside)
$6.30 (145.14% Upside)
Blogger Sentiment
Bearish
BTAI Sentiment 67%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 22.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.49%
12-Months-Change
Fundamentals
Return on Equity
-1766.94%
Trailing 12-Months
Asset Growth
-64.20%
Trailing 12-Months
Company Description
Bioxcel Therapeutics Inc
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
---
BTAI Earnings Call
Q4 2024
0:00 / 0:00
---
BTAI Stock 12 Months Forecast
Average Price Target
$6.30
▲(145.14% Upside)
Technical Analysis
Best Analysts Covering BTAI
1 Year
1 Year Success Rate
12/36 ratings generated profit
1 Year Average Return
+52.62%
reiterated a buy rating 2 months ago
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +52.62% per trade.
---